CME (AMA PRA Category 1 Credit)

  2. Home
  3. Credit Type
  4. CME (AMA PRA Category 1 Credit)
  5. Specialty Area
Page 7 of 8
Results 451 - 525 of 571
rePlace2
Guideline-recommended Treatments for NTM
rePlace2
Diagnosis of NTM
rePlace2
Factors Associated with Respiratory Involvement in NTM
rePlace2
Most Common Species in NTM Lung Disease
rePlace2
Nontuberculous Mycobacteria: Introduction and Epidemiology
9808-0004
What’s New in Spinal Muscular Atrophy? Reporting from Dallas
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
No image set
New Therapies, New Opportunities and New Challenges in Managing NTM
No image set
Updates in Inoperable CTEPH
9808-0003
SMA Updates from Los Angeles
pah icon
PAH Today: Mastering Current, Tailored Treatment
No image set
Achieving Better Control of Severe Asthma
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
9808-0002
Updates in SMA and Gene Therapy from Arlington, VA
Proper_Use_of_an_Inhaler_264x150
Proper Use of an Inhaler
biosims-archmed icon23
Top Questions about Biosimilars in Dermatology
biosims-archmed icon1
Top Questions about Biosimilars in Gastroenterology
biosims-archmed icon2
Top Questions about Biosimilars in Rheumatology
biosims-archmed icon
Top Questions about Biosimilars in Hematology/Oncology
biosims-gastro2
Biosimilars and Patients with Inflammatory Bowel Disease
No image set
Nontuberculous Mycobacterial Lung Disease Today and Tomorrow
No image set
Exploring the Patient Journey with Problem-Based Learning
No image set
Genetics and Personalized Medicine for Patients with Pulmonary Fibrosis
No image set
Environmental Influences on the Development of Pulmonary Fibrosis
No image set
Gene Abnormalities and ILD
No image set
Exploring the Basic Mechanisms that Contribute to Development of Lung Fibrosis
No image set
Updates on Registry Enrollment and Growth of the Care Center Network
No image set
New Approaches to the Diagnosis of IPF
No image set
Exploring New Therapeutic Avenues for Managing PF
No image set
New Research on Mechanisms in the Development of PF
biosims-gastro1
Biosimilars: The New Era of Gastroenterology Management Considerations
No image set
Know Before You Go: IPF Grand Rounds Pre-learning
No image set
IPF Management Considerations
No image set
Perspectives on Side Effect Management
No image set
The Latest in IPF: Implications for Clinical Practice
No image set
Registry Data Provide Important Severity Indicators for PH
No image set
New Developments in the Diagnosis and Management of IPF
No image set
Palliative Care for Patients with IPF
No image set
Real World Experience in Patients with COPD
No image set
ICD-10 Codes and Nomenclature for Classification of PAH
No image set
Fleischner Society Update in Classification of IPF
No image set
Transbronchial Cryobiopsy for the Diagnosis of ILD
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
No image set
Optimizing Patient Outcomes in IPF
No image set
Understanding IPF as a Part of the Overall Scope of ILD
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
No image set
The Importance of Early Referral and Treatment
No image set
How to Recognize and Diagnose IPF
No image set
What Is IPF?
No image set
What’s Next for IPF Therapy?
No image set
Applying the Evidence on Antifibrotic Agents for IPF
No image set
What Do the Experts Say about New Developments in the Diagnosis of ILD?
No image set
Is the delivery system a good match for your patients with COPD?
No image set
Stepping up or stepping down – which direction for COPD patients?
No image set
What’s the 2017 GOLD standard for managing patients with COPD?
No image set
UIP, IPF, NSIP, CHP: Making Sense of the Letters
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
No image set
A Personalized Approach to Managing Patients with Uncontrolled Asthma
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
Page 7 of 8

Search